pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ROCHE · news · pharmadog
← back to ROCHE
News mentioning ROCHE
260
stories
-93m
Adecto, Aviceda shut down
biospace
3h
AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
endpoints
10h
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
19h
Genentech AI leader Richard Bonneau leaves pharma in latest exit
endpoints
23h
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
23h
Roche enlists Alector in Parkinson's deal, paying $100M upfront
endpoints
1d
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
biopharma dive
1d
Genentech pays Alector $100M for preclinical Parkinson’s prospect
fiercebiotech
1d
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
3d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
4d
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
4d
‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline
fiercebiotech
4d
3 takeaways from a European obesity scientific meeting
biopharma dive
4d
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
5d
Roche launches simultaneous screening test for SMA, SCID and SCD
fiercebiotech
5d
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
6d
STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
stat
6d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
6d
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
fiercebiotech
6d
#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's
endpoints
6d
STAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas
stat
6d
Canadian $5M accelerated clinical trial program cuts start-up to 45 days
fiercebiotech
7d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
7d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
7d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
7d
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
stat
7d
AI health startup Ortet launches with $500M and co-founders from Genentech
endpoints
7d
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
stat
7d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
7d
Kodiak skyrockets on positive study data for 2 eye drugs
biopharma dive
← prev
page 1 of 9
next →
